Patient Derived Xenograft (PDX) models involve implantation of intact patient tumors or tumor cells directly into immunodeficient mice. They allow cancer researchers to study cancer biology and test efficacy of new therapeutics in oncology research. PDX models more closely mimic the molecular, cellular, and tumor microenvironment characteristics compared to traditional cell line derived xenograft models. They preserve intratumoral heterogeneity and recapitulate key features of diverse tumor types, their genetic diversity, and therapeutic responses.
The global Patient Derived Xenograft Model Market is estimated to be valued at Us$ 30 Million In 2024 and is expected to exhibit a CAGR Of 4.0% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of Patient Derived Xenograft Models in oncology research is one of the major trends driving the growth of the market. PDX models allow researchers to understand cancer biology, discover biomarkers, validate drug targets and study tumor evolution in a whole living system. They are well suited for modeling cancer drug resistance, metastasis and evaluating therapeutic strategies. Major cancer institutes and pharmaceutical companies are investing significantly to develop biobanks of PDX models that can be used for precision medicine research and drug development. This is expected to fuel demand and support market growth over the forecast period.
Segment Analysis
Patient Derived Xenograft Model Market is segmented based on type, application, and end user. The patient derived tumor xenograft segment currently holds the largest market share owing to its ability to capture tumor properties, anticancer drug responses for personalized cancer therapies. Patient derived tumor xenograft models offer promising prospects for predictive cancer modeling and precision oncology applications.
Key Takeaways
The Global Patient Derived Xenograft Model Market Demand is expected to witness high growth during the forecast period from 2024 to 2031. The global Patient Derived Xenograft Model Market is estimated to be valued at US$ 30 million in 2024 and is expected to exhibit a CAGR of 4.0% over the forecast period 2024 to 2031.
North America currently accounts for the largest share of the global market due to increase in cancer research activities. Growing federal funding for cancer research and presence of key players in the region will further drive the growth. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to rising investments in healthcare sector by major countries like China and India.
Key players operating in the Patient Derived Xenograft Model Market are Charles River Laboratories, Crown Bioscience Inc., WuXi AppTec, Champions Oncology, Oncodesign, Janviance, Greenland Biotech, EPO Berlin-Buch Gmbh, Xentech, Urolead.
Get more insights on this topic :
